Indian Peptides and Heparin Market by Type (Insulin, Teriparatide, Liraglutide, Leuprolide, Leuprolide, Exenatide, Calcitonin, Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Infectious Diseases, Cancer, Osteoporosis) - Forecast to 2022
“Indian Peptides and Heparin Market projected to grow at a CAGR of 15.0% and 4.9% respectively”
The Indian peptides market is expected to reach USD 883.0 million in 2022 from USD 381.8 million in 2016 and is expected to register a CAGR of 15.0%, and the Indian heparin market is projected to reach USD 170.2 million by 2022, at a CAGR of 4.9%. Factors such as increasing prevalence of chronic diseases, increasing incidence of coagulation disorder, and favorable government policies are the major driving factors for the Indian peptides and heparin market. On the other hand, the availability of alternative drugs is the major restraining factor for the Indian peptides market. The patent expiry of blockbuster drugs will provide growth opportunities to players in the Indian peptides market. For example, Victorza is the brand name of the liraglutide peptide developed by Novo Nordisk. Its patent will expire in August 2017, which will enable drug manufacturers to introduce their generic versions of it.
“Bivalirudin type is expected to register the highest growth during the forecast period”
The Indian peptides market is classified on the basis of type into insulin, teriparatide, liraglutide, glucagon, leuprolide acetate, octreotide acetate, calcitonin salmon, triptorelin, eptifibatide, glatiramer acetate, bivalirudin, exenatide, and other molecules. The bivalirudin segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the increasing number of percutaneous coronary intervention procedures (PCI) in India.
“Awareness about early diagnosis drives growth of the diabetes segment”
By application, the Indian peptides market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological applications, and other applications. The diabetes segment is expected to register highest CAGR during the forecast period. The growth in this segment can be primarily attributed to increasing awareness of early diagnosis, increasing prevalence & incidence of diabetes, and increasing aging population.
Key players operating in the Indian peptides market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).
“Enoxaparin sodium type is expected to register the highest growth during the forecast period”
The Indian heparin market is classified on the basis of type into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. The enoxaparin sodium type segment is expected to register the highest growth during the forecast period. This growth can be attributed to the increasing coagulation disorders in the country.
Key players operating in the Indian heparin market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).
The primary interviews conducted for this report can be categorized as follows:
The report analyses the Indian peptides market by type and application and the Indian heparin market by type. Apart from comprehensive product analysis and market sizing, the report also provides the complete list of peptide and heparin manufacturers and marketing players in India. In addition, the report profiles companies with product portfolios and key financial data by key players to maintain and increase their shares in the market. The abovementioned market research data, market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.
The report provides insights on the following strategies:
The Indian peptides market is expected to reach USD 883.0 million in 2022 from USD 381.8 million in 2016 and is expected to register a CAGR of 15.0%, and the Indian heparin market is projected to reach USD 170.2 million by 2022, at a CAGR of 4.9%. Factors such as increasing prevalence of chronic diseases, increasing incidence of coagulation disorder, and favorable government policies are the major driving factors for the Indian peptides and heparin market. On the other hand, the availability of alternative drugs is the major restraining factor for the Indian peptides market. The patent expiry of blockbuster drugs will provide growth opportunities to players in the Indian peptides market. For example, Victorza is the brand name of the liraglutide peptide developed by Novo Nordisk. Its patent will expire in August 2017, which will enable drug manufacturers to introduce their generic versions of it.
“Bivalirudin type is expected to register the highest growth during the forecast period”
The Indian peptides market is classified on the basis of type into insulin, teriparatide, liraglutide, glucagon, leuprolide acetate, octreotide acetate, calcitonin salmon, triptorelin, eptifibatide, glatiramer acetate, bivalirudin, exenatide, and other molecules. The bivalirudin segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to the increasing number of percutaneous coronary intervention procedures (PCI) in India.
“Awareness about early diagnosis drives growth of the diabetes segment”
By application, the Indian peptides market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological applications, and other applications. The diabetes segment is expected to register highest CAGR during the forecast period. The growth in this segment can be primarily attributed to increasing awareness of early diagnosis, increasing prevalence & incidence of diabetes, and increasing aging population.
Key players operating in the Indian peptides market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. Reddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India).
“Enoxaparin sodium type is expected to register the highest growth during the forecast period”
The Indian heparin market is classified on the basis of type into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. The enoxaparin sodium type segment is expected to register the highest growth during the forecast period. This growth can be attributed to the increasing coagulation disorders in the country.
Key players operating in the Indian heparin market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).
The primary interviews conducted for this report can be categorized as follows:
- By Company Type - Tier 1 – 70 %, Tier 2 – 30%
- By Designation – C level – 62%, Director level – 21%, Others – 17%
The report analyses the Indian peptides market by type and application and the Indian heparin market by type. Apart from comprehensive product analysis and market sizing, the report also provides the complete list of peptide and heparin manufacturers and marketing players in India. In addition, the report profiles companies with product portfolios and key financial data by key players to maintain and increase their shares in the market. The abovementioned market research data, market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions to be successful in the market.
Benefits of Buying this Report:
This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.
The report provides insights on the following strategies:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Indian peptides and heparin market. The report analyses the Indian peptides market by type and application and the Indian heparin market by type.
- Competitive Assessment: In-depth assessment of the market strategies, business segments, and product portfolios of the leading players in the Indian peptides and heparin market.
1 INDIAN PEPTIDES MARKET OVERVIEW
1.1 INTRODUCTION
1.2 INDIAN PEPTIDES MARKET DYNAMICS
1.2.1 DRIVERS
1.2.1.1 Rising incidence of diseases
1.2.1.2 Favorable government initiatives for the pharmaceutical sector
1.2.2 RESTRAINT
1.2.2.1 Availability of alternative drugs
1.2.3 OPPORTUNITY
1.2.3.1 Patent expiry of blockbuster peptides
1.2.4 CHALLENGE
1.2.4.1 Regulatory and pricing issues
2 INDIAN PEPTIDES MARKET, BY TYPE
2.1 INTRODUCTION
2.2 INSULIN
2.2.1 INSULIN MARKET : COMPANIES WITH PIPELINE PRODUCT
2.3 TERIPARATIDE
2.3.1 TERIPARATIDE ACETATE MARKET: COMPANIES WITH PIPELINE PRODUCTS
2.4 LIRAGLUTIDE
2.5 LEUPROLIDE ACETATE
2.5.1 LEUPROLIDE ACETATE MARKET: COMPANIES WITH PIPELINE PRODUCTS
2.6 OCTREOTIDE ACETATE
2.7 CALCITONIN-SALMON
2.8 TRIPTORELIN
2.9 EPTIFIBATIDE
2.10 GLATIRAMER ACETATE
2.11 BIVALIRUDIN
2.12 GLUCAGON
2.13 EXENATIDE
2.13.1 EXENATIDE MARKET: COMPANEIS WITH PIPELINE PRODUCTS
2.14 OTHER MOLECULES
3 INDIAN PEPTIDES MARKET, BY APPLICATION
3.1 INTRODUCTION
3.2 DIABETES
3.3 INFECTIOUS DISEASES
3.4 CANCER
3.5 OSTEOPOROSIS
3.6 CARDIOLOGY
3.7 GYNECOLOGY
3.8 OTHER APPLICATIONS
4 INDIAN PEPTIDES MARKET SHARE ANALYSIS
5 INDIAN PEPTIDES MARKET COMPANY PROFILES
(Business Overview, Products Offered)*
5.1 BIOCON LIMITED
5.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
5.3 WOCKHARDT LTD.
5.4 INTAS PHARMACEUTICALS LTD.
5.5 CIPLA LIMITED
5.6 EMCURE PHARMACEUTICALS PVT. LTD.
5.7 ZYDUS CADILA
5.8 BHARAT SERUM AND VACCINES LIMITED
5.9 NATCO PHARMA LIMITED
5.10 DR. REDDY'S LABORATORIES
*Details on MarketsandMarkets view, Business Overview, Products Offered might not be captured in case of unlisted companies.
6 INDIAN HEPARIN MARKET OVERVIEW
6.1 INTRODUCTION
6.2 INDIAN HEPARIN MARKET DYNAMICS
6.2.1 DRIVERS
6.2.1.1 Growing incidence of coagulation disorders
6.2.1.2 Government support for the pharmaceutical industry
6.2.2 RESTRAINT
6.2.2.1 High degree of consolidation to hinder small players from entering the market
6.2.3 CHALLENGE
6.2.3.1 Regulatory and pricing issues
7 INDIAN HEPARIN MARKET, BY TYPE
7.1 INTRODUCTION
7.2 ENOXAPARIN SODIUM
7.2.1.1 Enoxaparin sodium market: Companies with pipeline products
7.3 HEPARIN SODIUM
7.4 FONDAPARINUX
7.4.1.1 Fondaparinux market: Companies with pipeline products
7.5 DALTEPARIN SODIUM
7.5.1.1 Dalteparin sodium market: Companies with pipeline products
8 INDIAN HEPARIN MARKET SHARE ANALYSIS
9 INDIAN HEPARIN MARKET COMPANY PROFILES
(Business Overview, Products Offered)*
9.1 CIPLA LTD.
9.2 EMCURE PHARMACEUTICALS PVT. LTD.
9.3 GLAND PHARMA LIMITED
9.4 TROIKAA PHARMACEUTICALS LTD.
9.5 BIOLOGICAL E LIMITED
9.6 BHARAT BIOTECH
9.7 SAMARTH LIFE SCIENCES PVT. LTD.
9.8 VHB LIFE SCIENCES LIMITED
9.9 CELON LABORATORIES PVT. LTD.
9.10 UNITED BIOTECH (P) LIMITED
*Details on MarketsandMarkets view, Business Overview, Products Offered might not be captured in case of unlisted companies.
9.11 AUTHOR DETAILS
1.1 INTRODUCTION
1.2 INDIAN PEPTIDES MARKET DYNAMICS
1.2.1 DRIVERS
1.2.1.1 Rising incidence of diseases
1.2.1.2 Favorable government initiatives for the pharmaceutical sector
1.2.2 RESTRAINT
1.2.2.1 Availability of alternative drugs
1.2.3 OPPORTUNITY
1.2.3.1 Patent expiry of blockbuster peptides
1.2.4 CHALLENGE
1.2.4.1 Regulatory and pricing issues
2 INDIAN PEPTIDES MARKET, BY TYPE
2.1 INTRODUCTION
2.2 INSULIN
2.2.1 INSULIN MARKET : COMPANIES WITH PIPELINE PRODUCT
2.3 TERIPARATIDE
2.3.1 TERIPARATIDE ACETATE MARKET: COMPANIES WITH PIPELINE PRODUCTS
2.4 LIRAGLUTIDE
2.5 LEUPROLIDE ACETATE
2.5.1 LEUPROLIDE ACETATE MARKET: COMPANIES WITH PIPELINE PRODUCTS
2.6 OCTREOTIDE ACETATE
2.7 CALCITONIN-SALMON
2.8 TRIPTORELIN
2.9 EPTIFIBATIDE
2.10 GLATIRAMER ACETATE
2.11 BIVALIRUDIN
2.12 GLUCAGON
2.13 EXENATIDE
2.13.1 EXENATIDE MARKET: COMPANEIS WITH PIPELINE PRODUCTS
2.14 OTHER MOLECULES
3 INDIAN PEPTIDES MARKET, BY APPLICATION
3.1 INTRODUCTION
3.2 DIABETES
3.3 INFECTIOUS DISEASES
3.4 CANCER
3.5 OSTEOPOROSIS
3.6 CARDIOLOGY
3.7 GYNECOLOGY
3.8 OTHER APPLICATIONS
4 INDIAN PEPTIDES MARKET SHARE ANALYSIS
5 INDIAN PEPTIDES MARKET COMPANY PROFILES
(Business Overview, Products Offered)*
5.1 BIOCON LIMITED
5.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
5.3 WOCKHARDT LTD.
5.4 INTAS PHARMACEUTICALS LTD.
5.5 CIPLA LIMITED
5.6 EMCURE PHARMACEUTICALS PVT. LTD.
5.7 ZYDUS CADILA
5.8 BHARAT SERUM AND VACCINES LIMITED
5.9 NATCO PHARMA LIMITED
5.10 DR. REDDY'S LABORATORIES
*Details on MarketsandMarkets view, Business Overview, Products Offered might not be captured in case of unlisted companies.
6 INDIAN HEPARIN MARKET OVERVIEW
6.1 INTRODUCTION
6.2 INDIAN HEPARIN MARKET DYNAMICS
6.2.1 DRIVERS
6.2.1.1 Growing incidence of coagulation disorders
6.2.1.2 Government support for the pharmaceutical industry
6.2.2 RESTRAINT
6.2.2.1 High degree of consolidation to hinder small players from entering the market
6.2.3 CHALLENGE
6.2.3.1 Regulatory and pricing issues
7 INDIAN HEPARIN MARKET, BY TYPE
7.1 INTRODUCTION
7.2 ENOXAPARIN SODIUM
7.2.1.1 Enoxaparin sodium market: Companies with pipeline products
7.3 HEPARIN SODIUM
7.4 FONDAPARINUX
7.4.1.1 Fondaparinux market: Companies with pipeline products
7.5 DALTEPARIN SODIUM
7.5.1.1 Dalteparin sodium market: Companies with pipeline products
8 INDIAN HEPARIN MARKET SHARE ANALYSIS
9 INDIAN HEPARIN MARKET COMPANY PROFILES
(Business Overview, Products Offered)*
9.1 CIPLA LTD.
9.2 EMCURE PHARMACEUTICALS PVT. LTD.
9.3 GLAND PHARMA LIMITED
9.4 TROIKAA PHARMACEUTICALS LTD.
9.5 BIOLOGICAL E LIMITED
9.6 BHARAT BIOTECH
9.7 SAMARTH LIFE SCIENCES PVT. LTD.
9.8 VHB LIFE SCIENCES LIMITED
9.9 CELON LABORATORIES PVT. LTD.
9.10 UNITED BIOTECH (P) LIMITED
*Details on MarketsandMarkets view, Business Overview, Products Offered might not be captured in case of unlisted companies.
9.11 AUTHOR DETAILS
LIST OF TABLES
Table 1 INCIDENCE OF CANCER CASES IN INDIA, 2015 VS 2025
Table 2 PEPTIDES AND THEIR ALTERNATIVES
Table 3 INDIAN PEPTIDES MARKET, BY TYPE, 2016–2022 (USD MILLION)
Table 4 INSULIN MARKET: MANUFACTURERS AND BRANDS
Table 5 INSULIN MARKET: KEY PLAYERS AND BRANDS
Table 6 TERIPARATIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 7 TERIPARATIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 8 LIRAGLUTIDE MARKET: KEY PLAYERS AND BRANDS
Table 9 LEUPROLIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 10 LEUPROLIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 11 OCTREOTIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 12 OCTREOTIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 13 CALCITONIN-SALMON MARKET: MANUFACTURERS AND BRANDS
Table 14 CALCITONIN-SALMON MARKET: KEY PLAYERS AND BRANDS
Table 15 TRIPTORELIN MARKET: MANUFACTURERS AND BRANDS
Table 16 TRIPTORELIN MARKET: KEY PLAYERS AND BRANDS
Table 17 EPTIFIBATIDE MARKET: MANUFACTURERS AND BRANDS
Table 18 EPTIFIBATIDE MARKET: KEY PLAYERS AND BRANDS
Table 19 GLATIRAMER ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 20 GLATIRAMER ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 21 BIVALIRUDIN MARKET: MANUFACTURERS AND BRANDS
Table 22 BIVALIRUDIN MARKET: KEY PLAYERS AND BRANDS
Table 23 GLUCAGON MARKET: KEY PLAYERS AND BRANDS
Table 24 EXENATIDE MARKET: KEY PLAYERS AND BRANDS
Table 25 COLISTIN MOLECULE: MANUFACTURERES AND BRANDS
Table 26 COLISTIN MARKET: KEY PLAYERS AND BRANDS
Table 27 ENALAPRIL MOLECULE: MANUFACTURERES AND BRANDS
Table 28 ENALAPRIL MARKET: KEY PLAYERS AND BRANDS
Table 29 CASPOFUNGIN: MANUFACTURERES AND BRANDS
Table 30 CASPOFUNGIN MARKET: KEY PLAYERS AND BRANDS
Table 31 BORTEZOMIB: MANUFACTURERES AND BRANDS
Table 32 BORTEZOMIB MARKET: KEY PLAYERS AND BRANDS
Table 33 OXYTOCIN: MANUFACTURERS AND BRANDS
Table 34 OXYTOCIN MARKET: KEY PLAYERS AND BRANDS
Table 35 INDIAN PEPTIDES MARKET SIZE, BY APPLICATION, 2016–2022 (USD MILLION)
Table 36 INCIDENCE OF CANCER CASES IN INDIA, 2015 VS 2025
Table 37 INDIAN HEPARIN MARKET, BY TYPE, 2016–2022 (USD MILLION)
Table 38 ENOXAPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
Table 39 ENOXAPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
Table 40 HEPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
Table 41 HEPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
Table 42 FONDAPARINUX MARKET: MANUFACTURERS AND BRANDS
Table 43 FONDAPARINUX MARKET: KEY PLAYERS AND BRANDS
Table 44 DALTEPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
Table 45 DALTEPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
Table 1 INCIDENCE OF CANCER CASES IN INDIA, 2015 VS 2025
Table 2 PEPTIDES AND THEIR ALTERNATIVES
Table 3 INDIAN PEPTIDES MARKET, BY TYPE, 2016–2022 (USD MILLION)
Table 4 INSULIN MARKET: MANUFACTURERS AND BRANDS
Table 5 INSULIN MARKET: KEY PLAYERS AND BRANDS
Table 6 TERIPARATIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 7 TERIPARATIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 8 LIRAGLUTIDE MARKET: KEY PLAYERS AND BRANDS
Table 9 LEUPROLIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 10 LEUPROLIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 11 OCTREOTIDE ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 12 OCTREOTIDE ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 13 CALCITONIN-SALMON MARKET: MANUFACTURERS AND BRANDS
Table 14 CALCITONIN-SALMON MARKET: KEY PLAYERS AND BRANDS
Table 15 TRIPTORELIN MARKET: MANUFACTURERS AND BRANDS
Table 16 TRIPTORELIN MARKET: KEY PLAYERS AND BRANDS
Table 17 EPTIFIBATIDE MARKET: MANUFACTURERS AND BRANDS
Table 18 EPTIFIBATIDE MARKET: KEY PLAYERS AND BRANDS
Table 19 GLATIRAMER ACETATE MARKET: MANUFACTURERS AND BRANDS
Table 20 GLATIRAMER ACETATE MARKET: KEY PLAYERS AND BRANDS
Table 21 BIVALIRUDIN MARKET: MANUFACTURERS AND BRANDS
Table 22 BIVALIRUDIN MARKET: KEY PLAYERS AND BRANDS
Table 23 GLUCAGON MARKET: KEY PLAYERS AND BRANDS
Table 24 EXENATIDE MARKET: KEY PLAYERS AND BRANDS
Table 25 COLISTIN MOLECULE: MANUFACTURERES AND BRANDS
Table 26 COLISTIN MARKET: KEY PLAYERS AND BRANDS
Table 27 ENALAPRIL MOLECULE: MANUFACTURERES AND BRANDS
Table 28 ENALAPRIL MARKET: KEY PLAYERS AND BRANDS
Table 29 CASPOFUNGIN: MANUFACTURERES AND BRANDS
Table 30 CASPOFUNGIN MARKET: KEY PLAYERS AND BRANDS
Table 31 BORTEZOMIB: MANUFACTURERES AND BRANDS
Table 32 BORTEZOMIB MARKET: KEY PLAYERS AND BRANDS
Table 33 OXYTOCIN: MANUFACTURERS AND BRANDS
Table 34 OXYTOCIN MARKET: KEY PLAYERS AND BRANDS
Table 35 INDIAN PEPTIDES MARKET SIZE, BY APPLICATION, 2016–2022 (USD MILLION)
Table 36 INCIDENCE OF CANCER CASES IN INDIA, 2015 VS 2025
Table 37 INDIAN HEPARIN MARKET, BY TYPE, 2016–2022 (USD MILLION)
Table 38 ENOXAPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
Table 39 ENOXAPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
Table 40 HEPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
Table 41 HEPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
Table 42 FONDAPARINUX MARKET: MANUFACTURERS AND BRANDS
Table 43 FONDAPARINUX MARKET: KEY PLAYERS AND BRANDS
Table 44 DALTEPARIN SODIUM MARKET: MANUFACTURERS AND BRANDS
Table 45 DALTEPARIN SODIUM MARKET: KEY PLAYERS AND BRANDS
LIST OF FIGURES
Figure 1 INDIAN PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 2 DRUG APPROVALS IN INDIA
Figure 3 OTHER MOLECULES: MARKET SHARE, 2016
Figure 4 INDIAN PEPTIDES MARKET SHARE, BY KEY PLAYER, 2016
Figure 5 COMPANY SNAPSHOT: BIOCON LIMITED (2016)
Figure 6 COMPANY SNAPSHOT: SUN PHARMACEUTICAL INDUSTRIES LTD (2016)
Figure 7 COMPANY SNAPSHOT: WOCKHARDT LTD. (2016)
Figure 8 COMPANY SNAPSHOT: INTAS PHARMACEUTICALS LTD (2016)
Figure 9 COMPANY SNAPSHOT: CIPLA LIMITED(2016)
Figure 10 COMPANY SNAPSHOT: ZYDUS CADILA (2016)
Figure 11 COMPANY SNAPSHOT: NATCO PHARMA LIMITED (2016)
Figure 12 COMPANY SNAPSHOT: DR. REDDY’S LABORATORIES (2016)
Figure 13 INDIAN HEPARIN MARKET: DRIVERS, RESTRAINTS, AND CHALLENGES
Figure 14 INDIAN HEPARIN MARKET SHARE, BY KEY PLAYER, 2016
Figure 15 COMPANY SANPSHOT: CIPLA LTD.
Figure 1 INDIAN PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 2 DRUG APPROVALS IN INDIA
Figure 3 OTHER MOLECULES: MARKET SHARE, 2016
Figure 4 INDIAN PEPTIDES MARKET SHARE, BY KEY PLAYER, 2016
Figure 5 COMPANY SNAPSHOT: BIOCON LIMITED (2016)
Figure 6 COMPANY SNAPSHOT: SUN PHARMACEUTICAL INDUSTRIES LTD (2016)
Figure 7 COMPANY SNAPSHOT: WOCKHARDT LTD. (2016)
Figure 8 COMPANY SNAPSHOT: INTAS PHARMACEUTICALS LTD (2016)
Figure 9 COMPANY SNAPSHOT: CIPLA LIMITED(2016)
Figure 10 COMPANY SNAPSHOT: ZYDUS CADILA (2016)
Figure 11 COMPANY SNAPSHOT: NATCO PHARMA LIMITED (2016)
Figure 12 COMPANY SNAPSHOT: DR. REDDY’S LABORATORIES (2016)
Figure 13 INDIAN HEPARIN MARKET: DRIVERS, RESTRAINTS, AND CHALLENGES
Figure 14 INDIAN HEPARIN MARKET SHARE, BY KEY PLAYER, 2016
Figure 15 COMPANY SANPSHOT: CIPLA LTD.
